Progress in Liver Cancer Associated to Autoimmune Liver Disease
DOI:
https://doi.org/10.53469/jcmp.2025.07(02).20Keywords:
Autoimmune liver disease-related liver cancer, Autoimmune hepatitis, Primary biliary cholangitis, Primary sclerosing cholangitisAbstract
Autoimmune liver diseases (AILDs) are a group of liver diseases caused by abnormal autoimmune responses of the body, mainly including three main types: autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) [1]. Although the three diseases differ in their clinical manifestations and pathological mechanism, their common feature is the abnormal attack of the immune system on the liver tissue, resulting in impaired liver function. Primary liver cancer is considered the sixth most commonly diagnosed type of cancer worldwide, and it is also the third leading cause of death. The disease mainly includes hepatocellular carcinoma (HCC), intrahepatic cholangiocellular carcinoma (ICC) and other special types of liver cancer [2, 3]. There is a correlation between autoimmune liver disease and liver cancer, which has attracted wide attention from the medical community in recent years. Previous studies have reported that patients with AILDs will have a 3.6 times increased risk of developing cancer, while the risk of death from cancer will increase by 2.48 times. In addition to hepatobiliary cancer, several studies have further revealed that AILDs may also be complicated by colorectal cancer, hematological malignancies, pancreatic cancer, and skin cancer [4]. Therefore, this article will review the epidemiology, pathogenesis, risk factors, treatment prognosis and preventive surveillance of liver cancer associated with autoimmune liver disease.
References
Xiao X, Ma X. Autoimmune Hepatitis [J]. Heptology, 2023,28(01):25-27.
Razumilava N, Gores G J. Cholangiocarcinoma [J]. Lancet, 2014,383(9935):2168-2179.
Zhou J, Sun H C, Wang Z, et al. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition) [J]. Liver Cancer, 2018, 7(3): 235-260.
Li Z, Zhao D, Feng X, et al. Analysis of autoantibody characteristics in patients with liver cancer caused by primary biliary cirrhosis [J]. The Chinese Experimental Diagnostics, 2014,18(01):59-61.
Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin, 2021,71(3):209-249.
Trivedi P J, Hirschfield G M. Recent advances in clinical practice: epidemiology of autoimmune liver diseases [J]. Gut, 2021,70(10):1989-2003.
Lv T, Li M, Zeng N, et al. Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population [J]. J Gastroenterol Hepatol, 2019, 34(10): 1676-1684.
Danielsson B Å, Almer S, Prytz H, et al. Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis--a long-term follow-up study in 634 Swedish patients [J]. Scand J Gastroenterol, 2015,50(2):217-223.
Yan L J, Yao S Y, Meng G X, et al. Sex and regional disparities in incidence of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis [J]. Hepatol Int, 2021,15(6):1413-1420.
Wong R J, Gish R, Frederick T, et al. Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series [J]. Dig Dis Sci, 2011, 56(2): 578-585.
Choi J, Choi G H, Lee D, et al. Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country [J]. Liver Int, 2019,39(5):985-994.
Colapietro F, Maisonneuve P, Lytvyak E, et al. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis [J]. J Hepatol, 2024,80(1):53-61.
Dave S, Park S, Murad M H, et al. Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis [J]. Hepatology, 2021,73(1):68-78.
Morgan R L, Baack B, Smith B D, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies [J]. Ann Intern Med, 2013,158(5 Pt 1):329-337.
Natarajan Y, Tansel A, Patel P, et al. Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis [J]. Dig Dis Sci, 2021,66(7):2439-2451.
John B V, Aitcheson G, Schwartz K B, et al. Male Sex Is Associated With Higher Rates of Liver-Related Mortality in Primary Biliary Cholangitis and Cirrhosis [J]. Hepatology, 2021,74(2):879-891.
You H, Ma X, Efe C, et al. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis [J]. Hepatol Int, 2022, 16(1):1-23.
Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis [J]. J Hepatol, 2002,36(3):321-327.
Weismüller T J, Trivedi P J, Bergquist A, et al. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis [J]. Gastroenterology, 2017, 152(8): 1975-1984.
Gulamhusein A F, Eaton J E, Tabibian J H, et al. Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD [J]. Am J Gastroenterol, 2016,111(5):705-711.
Takakura W R, Tabibian J H, Bowlus C L. The evolution of natural history of primary sclerosing cholangitis [J]. Curr Opin Gastroenterol, 2017,33(2):71-77.
Bosch D E, Zen Y, Boukhar S A, et al. Hepatocellular carcinoma in primary sclerosing cholangitis and primary biliary cholangitis: a clinical and pathological study in an uncommon but emerging setting [J]. Virchows Arch, 2021,479(6):1131-1143.
Boonstra K, Weersma R K, van Erpecum K J, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis [J]. Hepatology, 2013,58(6):2045-2055.
Schrumpf E, Boberg K M. Hepatic and extrahepatic malignancies and primary sclerosing cholangitis [J]. Gut, 2003,52(2):165.
Manninen P, Karvonen A L, Laukkarinen J, et al. Colorectal cancer and cholangiocarcinoma in patients with primary sclerosing cholangitis and inflammatory bowel disease [J]. Scand J Gastroenterol, 2015, 50(4): 423-428.
Arndtz K, Hirschfield G M. The Pathogenesis of Autoimmune Liver Disease [J]. Dig Dis, 2016, 34(4): 327-333.
Czaja A J. Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions [J]. World J Gastroenterol, 2019, 25(45):6579-6606.
Sangro B, Sarobe P, Hervás-Stubbs S, et al. Advances in immunotherapy for hepatocellular carcinoma [J]. Nat Rev Gastroenterol Hepatol, 2021,18(8):525-543.
Liu Q, Li J, Zhang W, et al. Glycogen accumulation and phase separation drives liver tumor initiation [J]. Cell, 2021,184(22):5559-5576.
He M M, Lo C H, Wang K, et al. Immune-Mediated Diseases Associated With Cancer Risks [J]. JAMA Oncol, 2022,8(2):209-219.
Martín-Villa J M, Vaquero-Yuste C, Molina-Alejandre M, et al. HLA-G: Too Much or Too Little? Role in Cancer and Autoimmune Disease [J]. Front Immunol, 2022,13:796054.
Long X Q, Liu M Z, Liu Z H, et al. Bile acids and their receptors: Potential therapeutic targets in inflammatory bowel disease [J]. World J Gastroenterol, 2023,29(27):4252-4270.
Fu T, Li Y, Oh T G, et al. FXR mediates ILC-intrinsic responses to intestinal inflammation [J]. Proc Natl Acad Sci U S A, 2022,119(51):e2081926177.
McGee E E, Castro F A, Engels E A, et al. Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults [J]. Int J Cancer, 2019,144(4):707-717.
Zollner G, Trauner M. Mechanisms of cholestasis [J]. Clin Liver Dis, 2008,12(1):1-26.
Yang X, Xu Y, Li J, et al. Bile acid-gut microbiota imbalance in cholestasis and its long-term effect in mice [J]. mSystems, 2024,9(7):e12724.
Labib P L, Goodchild G, Pereira S P. Molecular Pathogenesis of Cholangiocarcinoma [J]. BMC Cancer, 2019,19(1):185.
Ioannou G N, Splan M F, Weiss N S, et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis [J]. Clin Gastroenterol Hepatol, 2007, 5(8): 938-945, 941-945.
Czaja A J. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis [J]. Dig Dis Sci, 2013,58(6):1459-1476.
Perera M H, Lugo L, Altshuler E. Hepatocellular Carcinoma in Patients With Liver Cirrhosis Secondary to Autoimmune Hepatitis: A Case Series and Literature Review [J]. Cureus, 2022,14(10):e30698.
Montano-Loza A J, Carpenter H A, Czaja A J. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis [J]. Am J Gastroenterol, 2008, 103(8):1944-1951.
Rigopoulou E I, Dalekos G N. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases [J]. Cancers (Basel), 2021,13(5).
Tansel A, Katz L H, El-Serag H B, et al. Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis [J]. Clin Gastroenterol Hepatol, 2017, 15(8):1207-1217.
Trivedi P J, Lammers W J, van Buuren H R, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study [J]. Gut, 2016,65(2):321-329.
Sy A M, Ferreira R D, John B V. Hepatocellular Carcinoma in Primary Biliary Cholangitis [J]. Clin Liver Dis, 2022,26(4):691-704.
Sucher E, Sucher R, Gradistanac T, et al. Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies [J]. J Immunol Res, 2019,2019:9437043.
Gong H, Yao L, Li D. Analysis of prognostic risk factors for liver cancer associated with autoimmune hepatitis [J]. Medical forum magazine, 2017,38(09):121-122.
Sheng S, Wang H, Li J, et al. Clinical features, treatment and prognosis of autoimmune hepatitis [J]. The Journal of Gastroenterology and Hepatology, 2020, 29(01): 15-17.
Watanabe T, Soga K, Hirono H, et al. Features of hepatocellular carcinoma in cases with autoimmune hepatitis and primary biliary cirrhosis [J]. World J Gastroenterol, 2009,15(2):231-239.
Silveira M G, Suzuki A, Lindor K D. Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis [J]. Hepatology, 2008,48(4):1149-1156.
Lindor K D, Bowlus C L, Boyer J, et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases [J]. Hepatology, 2019,69(1):394-419.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Danlin Wang, Liang Song, Lei Guan, Yi Lu, Ying Han
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
